The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Open accessAbstract
BACKGROUND: Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome. METHODS: In this double-blind, placebo-controlled trial, we randomly assigned 15,526 patients with a recent acute coronary syndrome to receive twice-daily doses of either 2.5 mg or 5 mg of rivaroxaban or placebo for a mean of 13 months and up to 31 months. The primary efficacy end point was a composite of death from cardiovascular causes, myocardial infarction, or stroke. RESULTS: Rivaroxaban significantly reduced the primary efficacy end point, as compared with placebo, with respective rates of 8.9% and 10.7% (hazard ratio in the rivaroxaban group, 0.84; 95% confidence interval [CI], 0.74 to 0.96; P=0.008), with significant improvement for both the twice-daily 2.5-mg dose (9.1% vs. 10.7%, P=0.02) and the twice-daily 5-mg dose (8.8% vs. 10.7%, P=0.03). The twice-daily 2.5-mg dose of rivaroxaban reduced the rates of death from cardiovascular causes (2.7% vs. 4.1%, P=0.002) and from any cause (2.9% vs. 4.5%, P=0.002), a survival benefit that was not seen with the twice-daily 5-mg dose. As compared with placebo, rivaroxaban increased the rates of major bleeding not related to coronary-artery bypass grafting (2.1% vs. 0.6%, P<0.001) and intracranial hemorrhage (0.6% vs. 0.2%, P=0.009), without a significant increase in fatal bleeding (0.3% vs. 0.2%, P=0.66) or other adverse events. The twice-daily 2.5-mg dose resulted in fewer fatal bleeding events than the twice-daily 5-mg dose (0.1% vs. 0.4%, P=0.04). CONCLUSIONS: In patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke. Rivaroxaban increased the risk of major bleeding and intracranial hemorrhage but not the risk of fatal bleeding. (Funded by Johnson & Johnson and Bayer Healthcare; ATLAS ACS 2-TIMI 51 ClinicalTrials.gov number, NCT00809965.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citationClinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
Eikelboom, J. W., Mehta, S. R., Anand, S. S., Xie, C., Fox, K. A. A., & Yusuf, S. (2006) · Circulation · doi:10.1161/circulationaha.106.612812 · Cited by 1,341
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Kakkar, A. K., Brenner, B., Dahl, O. E., Eriksson, B. I., Mouret, P., Muntz, J., Soglian, A. G., Pap, Á. F., Misselwitz, F., & Haas, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60880-6 · Cited by 1,070
Antman, E. M., McCabe, C. H., Gurfinkel, E. P., Turpie, A. G. G., Bernink, P. J. L. M., Salein, D., Bayes de Luna, A., Fox, K., Lablanche, J.-M., Radley, D., et al. (1999) · Circulation · doi:10.1161/01.cir.100.15.1593 · Cited by 1,052
Self-citationApixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105819 · Cited by 1,005
Self-citationTurpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
Mega, J., Braunwald, E., Mohanavelu, S., Burton, P., Poulter, R., Misselwitz, F., Hricak, V, Barnathan, E., Bordes, P., Witkowski, A., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60738-8 · Cited by 688
Self-citationLow-molecular-weight heparin during instability in coronary artery disease
Fragmin during Instability in Coronary Artery Disease (FRISC) study group (1996) · The Lancet · doi:10.1016/s0140-6736(96)91270-2 · Cited by 685
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.
Merlini, P. A., Bauer, K. A., Oltrona, L., Ardissino, D., Cattaneo, M., Belli, C., Mannucci, P. M., & Rosenberg, R. D. (1994) · Circulation · doi:10.1161/01.cir.90.1.61 · Cited by 597
Oldgren, J., Budaj, A., Granger, C. B., Khder, Y., Roberts, J., Siegbahn, A., Tijssen, J. G. P., Van de Werf, F., Wallentin, L., & for the RE-DEEM Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr113 · Cited by 534
APPRAISE Steering Committee and Investigators (2009) · Circulation · doi:10.1161/circulationaha.108.832139 · Cited by 461
Wallentin, L., Wilcox, R. G., Weaver, W. D., Emanuelsson, H., Goodvin, A., Nyström, P., & Bylock, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14287-0 · Cited by 370
Rothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E., & Cook, J. R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00005 · Cited by 334
Steg, P. G., Mehta, S. R., Jukema, J. W., Lip, G. Y. H., Gibson, C. M., Kovar, F., Kala, P., Garcia-Hernandez, A., Renfurm, R. W., & Granger, C. B. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr334 · Cited by 186
Self-citationNunnelee, J. D. (2011) · Journal of Vascular Nursing · doi:10.1016/j.jvn.2011.03.002 · Cited by 161
Gibson, C. M., Mega, J. L., Burton, P. B. J., Goto, S., Verheugt, F. W. A., Bode, C., Plotnikov, A. N., Sun, X., Cook‐Bruns, N., & Braunwald, E. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.01.026 · Cited by 96
Self-citation
Cited by
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
Authors/Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,829
Self-citation
Metadata
- Authors
- Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., Goto, S., Murphy, S. A., Plotnikov, A. N., Schneider, D., Sun, X., Verheugt, F. W. A., & Gibson, C. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-01-05
- Volume
- 366
- Issue
- 1
- Pages
- 9-19
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2117677020
- Cited by
- 1,897
- References
- 23
- FWCI
- 115.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.